Novavax has agreed to a deal to let Pfizer use Matrix-M adjuvant in its products for an upfront payment of $30 million and up to another $500 million in milestone payments. The biotech company said ...

Novavax secures a non-exclusive licensing deal with Pfizer, validating Matrix-M's platform value and shifting NVAX toward a technology provider model. NVAX receives $30M upfront, a potential $500M in ...

Pfizer is paying $30 million to use Novavax’s adjuvant technology to improve the efficacy of two of the Big Pharma’s vaccine programs. The tech, called Matrix-M, is designed to trigger an immune ...

In the dynamic environment of small to medium enterprises and startups, leaders often face a barrage of tasks demanding immediate attention. The Eisenhower Matrix, a strategic prioritization tool, ...

Jon has been an author at Android Police since 2021. He primarily writes features and editorials covering the latest Android news, but occasionally reviews hardware and Android apps. His favorite ...

Kelly-Ann Franklin has spent more than two decades in journalism which has helped her build a wide knowledge base of business and personal finance topics. Her goal with editing is to ensure tough ...